Abstract
Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, are the major determinant of chloroquine resistance in this lethal human malaria parasite. Here, we describe P. falciparum lines subjected to selection by amantadine or blasticidin that carry PfCRT mutations (C101F or L272F), causing the development of enlarged food vacuoles. These parasites also have increased sensitivity to chloroquine and some other quinoline antimalarials, but exhibit no or minimal change in sensitivity to artemisinins, when compared with parental strains. A transgenic parasite line expressing the L272F variant of PfCRT confirmed this increased chloroquine sensitivity and enlarged food vacuole phenotype. Furthermore, the introduction of the C101F or L272F mutation into a chloroquine-resistant variant of PfCRT reduced the ability of this protein to transport chloroquine by approximately 93 and 82%, respectively, when expressed in Xenopus oocytes. These data provide, at least in part, a mechanistic explanation for the increased sensitivity of the mutant parasite lines to chloroquine. Taken together, these findings provide new insights into PfCRT function and PfCRT-mediated drug resistance, as well as the food vacuole, which is an important target of many antimalarial drugs.
| Original language | American English |
|---|---|
| Article number | 14552 |
| Pages (from-to) | 14552 |
| Journal | Scientific Reports |
| Volume | 5 |
| State | Published - Sep 30 2015 |
Funding
This work was supported by the European Community’s Seventh Framework Programme, FP7/2007-2013 (Marie Curie-funded Initial Training Network InterMal, 215281-2 to SK and NanoMal, 304948 to SK and HMS), the NIH (R01 AI50234 to DAF and R01 AI071121 to RAC), the Australian National Health and Medical Research Council (Grant 1007035 and Fellowship 1053082 to REM) and the Burroughs Wellcome Fund - Investigators in Pathogenesis of Infectious Disease award (1007041.02 to ML).
| Funders | Funder number |
|---|---|
| Australian National Health and Medical Research Council | 1053082, 1007035 |
| FP7/2007 | 304948, 215281-2 |
| National Institutes of Health | R01 AI50234 |
| National Institute of Allergy and Infectious Diseases | R01AI071121 |
| Burroughs Wellcome Fund | 1007041.02 |
| Seventh Framework Programme |
Keywords
- Antiparasitic agents
- DNA sequencing
- Microscopy
- Parasite Biology
- Transmembrane protein PfCRT
- Xenopus laevis oocytes
- Malaria parasites
- Artemisinin
- Antimalarial
- Polymorphisms
- Mechanism
- Metaanalysis
- Piperaquine
- Expression
Disciplines
- Life Sciences
- Medicinal Chemistry and Pharmaceutics
- Parasitic Diseases
- Pharmacology, Toxicology and Environmental Health
- Biology
- Immunology and Infectious Disease
- Physiology